Dynamic changes of microbial flora and therapeutic consequences in persistent peritonitis

Critical Care

Volumn 19, Issue 1, 2015, Pages

  Montravers, Philippe ^a   Dufour, Guillaume ^a   Guglielminotti, Jean ^a   Desmard, Mathieu ^a   Muller, Claudette ^a   Houissa, Hamda ^a   Allou, Nicolas ^a   Marmuse, Jean Pierre ^a   Augustin, Pascal ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIFUNGAL AGENT; CARBAPENEM DERIVATIVE; CILASTATIN PLUS IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ADULT; ANASTOMOSIS LEAKAGE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEROIDES; CANDIDA; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MICROFLORA; MIDDLE AGED; MULTIDRUG RESISTANCE; NONHUMAN; PERITONEAL CAVITY; PERITONEAL FLUID; PERITONEUM LAVAGE; PERITONITIS; PERSISTENT PERITONITIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REOPERATION; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; TREATMENT DURATION; ASCITES FLUID; COMPARATIVE STUDY; ISOLATION AND PURIFICATION; MICROBIOLOGY; RISK FACTOR; SEPSIS; SEVERITY OF ILLNESS INDEX; TIME TO TREATMENT;

ANTI-BACTERIAL AGENTS; ASCITIC FLUID; CANDIDA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PERITONEAL LAVAGE; PERITONITIS; POSTOPERATIVE COMPLICATIONS; REOPERATION; RISK FACTORS; SEPSIS; SEVERITY OF ILLNESS INDEX; TIME-TO-TREATMENT;

EID: 84924856947     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-015-0789-9     Document Type: Article

References (40)

1. Koperna T, Schulz F. Relaparotomy in peritonitis: prognosis and treatment of patients with persisting intraabdominal infection. World J Surg. 2000;24:32-7.
2. Panhofer P, Izay B, Riedl M, Ferenc V, Ploder M, Jakesz R, et al. Age, microbiology and prognostic scores help to differentiate between secondary and tertiary peritonitis. Langenbeck's Arch Surg. 2009;394:265-71.
3. Weiss G, Meyer F, Lippert H. Infectiological diagnostic problems in tertiary peritonitis. Langenbeck's Arch Surg. 2006;391:473-82.
4. van Ruler O, Lamme B, Gouma DJ, Reitsma JB, Boermeester MA. Variables associated with positive findings at relaparotomy in patients with secondary peritonitis. Crit Care Med. 2007;35:468-76.
5. Nathens AB, Rotstein OD, Marshall JC. Tertiary peritonitis: clinical features of a complex nosocomial infection. World J Surg. 1998;22:158-63.
6. Chromik AM, Meiser A, Holling J, Sulberg D, Daigeler A, Meurer K, et al. Identification of patients at risk for development of tertiary peritonitis on a surgical intensive care unit. J Gastrointest Surg. 2009;13:1358-67.
7. Rotstein OD, Pruett TL, Simmons RL. Microbiologic features and treatment of persistent peritonitis in patients in the intensive care unit. Can J Surge. 1986;29:247-50.
8. Paugam-Burtz C, Dupont H, Marmuse JP, Chosidow D, Malek L, Desmonts JM, et al. Daily organ-system failure for diagnosis of persistent intra-abdominal sepsis after postoperative peritonitis. Intensive Care Med. 2002;28:594-8.
9. Marshall JC, Maier RV, Jimenez M, Dellinger EP. Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med. 2004;32:S513-26.
10. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:133-64.
11. de Ruiter J, Weel J, Manusama E, Kingma WP, van der Voort PH. The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis. Infection. 2009;37:522-7.
12. Augustin P, Kermarrec N, Muller-Serieys C, Lasocki S, Chosidow D, Marmuse JP, et al. Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. Crit Care. 2010;14:R20.
13. Seguin P, Fedun Y, Laviolle B, Nesseler N, Donnio PY, Malledant Y. Risk factors for multidrug-resistant bacteria in patients with post-operative peritonitis requiring intensive care. J Antimicrob Chemother. 2010;65:342-6.
14. Seguin P, Laviolle B, Chanavaz C, Donnio PY, Gautier-Lerestif AL, Campion JP, et al. Factors associated with multidrug-resistant bacteria in secondary peritonitis: impact on antibiotic therapy. Clin Microbiol Infect. 2006;12:980-5.
15. Roehrborn A, Thomas L, Potreck O, Ebener C, Ohmann C, Goretzki PE, et al. The microbiology of postoperative peritonitis. Clin Infect Dis. 2001;33:1513-9.
16. Unalp HR, Kamer E, Kar H, Bal A, Peskersoy M, Ali OM. Urgent abdominal re-explorations. World J Emerg Surg. 2006;1:10.
17. Societe Française de Microbiologie. Comité de l'antibiogramme. http://www.sfm-microbiologie.org/UserFiles/files/casfm/casfm_2011.pdf. Accessed 4 Jan 2015.
18. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-81.
19. Dupont H, Bourichon A, Paugam-Burtz C, Mantz J, Desmonts JM. Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med. 2003;31:752-7.
20. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957-63.
21. McCabe WR, Jackson GG. Gram-negative bacteremia. 1. Etiology and ecology. Arch Intern Med. 1962;110:847-55.
22. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707-10.
23. Buijk SL, Gyssens IC, Mouton JW, Van Vliet A, Verbrugh HA, Bruining HA. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother. 2002;49:121-8.
24. Karjagin J, Lefeuvre S, Oselin K, Kipper K, Marchand S, Tikkerberi A, et al. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther. 2008;83:452-9.
25. van Ruler O, Lamme B, de Vos R, Obertop H, Reitsma JB, Boermeester MA. Decision making for relaparotomy in secondary peritonitis. Dig Surg. 2008;25:339-46.
26. van Ruler O, Kiewiet JJ, Boer KR, Lamme B, Gouma DJ, Boermeester MA, et al. Failure of available scoring systems to predict ongoing infection in patients with abdominal sepsis after their initial emergency laparotomy. BMC Surg. 2011;11:38.
27. Hutchins RR, Gunning MP, Lucas DN, Allen-Mersh TG, Soni NC. Relaparotomy for suspected intraperitoneal sepsis after abdominal surgery. World J Surg. 2004;28:137-41.
28. Montravers P, Dupont H, Gauzit R, Veber B, Auboyer C, Blin P, et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med. 2006;34:646-52.
29. Montravers P, Lepape A, Dubreuil L, Gauzit R, Pean Y, Benchimol D, et al. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother. 2009;63:785-94.
30. Riche FC, Dray X, Laisne MJ, Mateo J, Raskine L, Sanson-Le Pors MJ, et al. Factors associated with septic shock and mortality in generalized peritonitis: comparison between community-acquired and postoperative peritonitis. Crit Care. 2009;13:R99.
31. Montravers P, Gauzit R, Muller C, Marmuse JP, Fichelle A, Desmonts JM. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis. 1996;23:486-94.
32. Augustin P, Dinh AT, Valin N, Desmard M, Crevecoeur MA, Muller-Serieys C, et al. Pseudomonas aeruginosa post-operative peritonitis: Clinical features, risk factors, and prognosis. Surg Infect. 2013;14:297-303.
33. Fierobe L, Decre D, Muller C, Lucet JC, Marmuse JP, Mantz J, et al. Methicillin-resistant Staphylococcus aureus as a causative agent of postoperative intra-abdominal infection: relation to nasal colonization. Clin Infect Dis. 1999;29:1231-8.
34. Fournier S, Brun-Buisson C, Jarlier V. Twenty years of antimicrobial resistance control programme in a regional multi hospital institution, with focus on emerging bacteria (VRE and CPE). Antimicrob Resist Infect Control. 2012;1:9.
35. Sotto A, Lefrant JY, Fabbro-Peray P, Muller L, Tafuri J, Navarro F, et al. Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J Antimicrob Chemother. 2002;50:569-76.
36. Venkatesh MP, Pham D, Fein M, Kong L, Weisman LE. Neonatal coinfection model of coagulase-negative Staphylococcus (Staphylococcus epidermidis) and Candida albicans: fluconazole prophylaxis enhances survival and growth. Antimicrob Agents Chemother. 2007;51:1240-5.
37. Peleg AY, Hogan DA, Mylonakis E. Medically important bacterial-fungal interactions. Nat Rev Microbiol. 2010;8:340-9.
38. Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med. 1999;27:1066-72.
39. Senn L, Eggimann P, Ksontini R, Pascual A, Demartines N, Bille J, et al. Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. Intensive Care Med. 2009;35:903-8.
40. De Waele JJ, Lipman J, Akova M, Bassetti M, Dimopoulos G, Kaukonen M, et al. Risk factors for target non-attainment during empirical treatment with beta-lactam antibiotics in critically ill patients. Intensive Care Med. 2014;40:1340-51.